413 related articles for article (PubMed ID: 16970020)
21. Early TIPS with covered stents versus standard treatment for acute variceal bleeding in patients with advanced cirrhosis: a randomised controlled trial.
Lv Y; Yang Z; Liu L; Li K; He C; Wang Z; Bai W; Guo W; Yu T; Yuan X; Zhang H; Xie H; Yao L; Wang J; Li T; Wang Q; Chen H; Wang E; Xia D; Luo B; Li X; Yuan J; Han N; Zhu Y; Niu J; Cai H; Xia J; Yin Z; Wu K; Fan D; Han G;
Lancet Gastroenterol Hepatol; 2019 Aug; 4(8):587-598. PubMed ID: 31153882
[TBL] [Abstract][Full Text] [Related]
22. Critical Care Management of Gastrointestinal Bleeding and Ascites in Liver Failure.
Rajwani K; Fortune BE; Brown RS
Semin Respir Crit Care Med; 2018 Oct; 39(5):566-577. PubMed ID: 30485887
[TBL] [Abstract][Full Text] [Related]
23. Transjugular intrahepatic portosystemic shunt and alfapump® system for refractory ascites in liver cirrhosis: Outcomes and complications.
Will V; Rodrigues SG; Stirnimann G; Gottardi A; Bosch J; Berzigotti A
United European Gastroenterol J; 2020 Oct; 8(8):961-969. PubMed ID: 32588789
[TBL] [Abstract][Full Text] [Related]
24. Diagnosis and Management of Cirrhosis and Its Complications: A Review.
Tapper EB; Parikh ND
JAMA; 2023 May; 329(18):1589-1602. PubMed ID: 37159031
[TBL] [Abstract][Full Text] [Related]
25. Current approaches to the management of patients with liver cirrhosis who have acute esophageal variceal bleeding.
Garbuzenko DV
Curr Med Res Opin; 2016; 32(3):467-75. PubMed ID: 26804426
[TBL] [Abstract][Full Text] [Related]
26. Current Management of the Complications of Cirrhosis and Portal Hypertension: Variceal Hemorrhage, Ascites, and Spontaneous Bacterial Peritonitis.
Garcia-Tsao G
Dig Dis; 2016; 34(4):382-6. PubMed ID: 27170392
[TBL] [Abstract][Full Text] [Related]
27. Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis.
Salerno F; Guevara M; Bernardi M; Moreau R; Wong F; Angeli P; Garcia-Tsao G; Lee SS
Liver Int; 2010 Aug; 30(7):937-47. PubMed ID: 20492521
[TBL] [Abstract][Full Text] [Related]
28. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation.
Testino G; Ferro C; Sumberaz A; Messa P; Morelli N; Guadagni B; Ardizzone G; Valente U
Hepatogastroenterology; 2003; 50(54):1753-5. PubMed ID: 14696397
[TBL] [Abstract][Full Text] [Related]
29. Management of ascites in the patient with portal hypertension with emphasis on spontaneous bacterial peritonitis.
Navasa M; Rodés J
Semin Gastrointest Dis; 1997 Oct; 8(4):200-9. PubMed ID: 9360284
[TBL] [Abstract][Full Text] [Related]
30. [Complications of liver cirrhosis - pharmaceutical versus interventional therapy].
Sturm L; Rössle M; Schultheiß M
Dtsch Med Wochenschr; 2019 Sep; 144(18):1259-1266. PubMed ID: 31514216
[TBL] [Abstract][Full Text] [Related]
31. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension.
Colombato L
J Clin Gastroenterol; 2007; 41 Suppl 3():S344-51. PubMed ID: 17975487
[TBL] [Abstract][Full Text] [Related]
32. [TIPS - Transjugular intrahepatic portosystemic shunt. A review].
Carreiro G; da Luz Moreira A; Murad FF; Azevedo F; Coelho HS
Arq Gastroenterol; 2001; 38(1):69-80. PubMed ID: 11586999
[TBL] [Abstract][Full Text] [Related]
33. Minimizing ascites. Complication of cirrhosis signals clinical deterioration.
Garcia N; Sanyal AJ
Postgrad Med; 2001 Feb; 109(2):91-6, 101-3. PubMed ID: 11272697
[TBL] [Abstract][Full Text] [Related]
34. Current and future pharmacological therapies for managing cirrhosis and its complications.
Kockerling D; Nathwani R; Forlano R; Manousou P; Mullish BH; Dhar A
World J Gastroenterol; 2019 Feb; 25(8):888-908. PubMed ID: 30833797
[TBL] [Abstract][Full Text] [Related]
35. Role of Transjugular Intrahepatic Portosystemic Shunt in the Management of Portal Hypertension: Review and Update of the Literature.
Hung ML; Lee EW
Clin Liver Dis; 2019 Nov; 23(4):737-754. PubMed ID: 31563220
[TBL] [Abstract][Full Text] [Related]
36. Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem.
Arroyo V; Jiménez W
J Hepatol; 2000; 32(1 Suppl):157-70. PubMed ID: 10728802
[TBL] [Abstract][Full Text] [Related]
37. Transjugular intrahepatic portosystemic shunt: current status.
Boyer TD
Gastroenterology; 2003 May; 124(6):1700-10. PubMed ID: 12761727
[TBL] [Abstract][Full Text] [Related]
38. Transjugular Intrahepatic Portosystemic Shunts With Covered Stents Increase Transplant-Free Survival of Patients With Cirrhosis and Recurrent Ascites.
Bureau C; Thabut D; Oberti F; Dharancy S; Carbonell N; Bouvier A; Mathurin P; Otal P; Cabarrou P; Péron JM; Vinel JP
Gastroenterology; 2017 Jan; 152(1):157-163. PubMed ID: 27663604
[TBL] [Abstract][Full Text] [Related]
39. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis.
Abraldes JG; Tarantino I; Turnes J; Garcia-Pagan JC; Rodés J; Bosch J
Hepatology; 2003 Apr; 37(4):902-8. PubMed ID: 12668985
[TBL] [Abstract][Full Text] [Related]
40. [The effect of portal hypertension on prognosis in patients with decompensated liver cirrhosis].
Zhang JY; Kuai JH; Jia JD; Wang BE; Qin CY
Zhonghua Gan Zang Bing Za Zhi; 2009 Apr; 17(4):263-5. PubMed ID: 19403023
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
